HROW Stock Forecast & Price Target

Harrow Inc is well-positioned within the eyecare pharmaceutical sector, particularly as the market for biosimilars continues to expand, achieving over 40% market share in certain therapeutic categories. The company reported a notable 22% quarter-over-quarter revenue growth for its product VEVYE, reaching $22.6 million in the third quarter of 2025, and has secured a 10.5% share of the national dry eye disease market. Expected future quarterly revenue run rates are projected to exceed $250 million by the fourth quarter of 2027, approximately four times higher than the actuals from the second quarter of 2025, reinforcing a positive long-term outlook for revenue and margin expansion based on their strategic and product development initiatives.

Harrow Inc faces significant financial challenges that contribute to a negative outlook, primarily due to the potential failure of its products developed by spinouts to generate favorable clinical data or obtain regulatory approval, which could severely impact the company's valuation. Additional risks include lower-than-expected market uptake, difficulties in product acquisition, inability to manage outstanding debt, and the reality of potential dilution stemming from necessary capital raising efforts. Furthermore, Harrow's status as a small company with limited resources raises concerns about its capacity to implement effective sales and marketing strategies, which may further hinder its operational success.